- Home
- SRTS vs PLRX Comparison
SRTS vs PLRX Comparison
Compare SRTS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- PLRX
- Stock Information
- Founded
- SRTS 2010
- PLRX 2015
- Country
- SRTS United States
- PLRX United States
- Employees
- SRTS N/A
- PLRX N/A
- Industry
- SRTS Medical/Dental Instruments
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- PLRX Health Care
- Exchange
- SRTS Nasdaq
- PLRX Nasdaq
- Market Cap
- SRTS 83.9M
- PLRX 84.7M
- IPO Year
- SRTS 2016
- PLRX 2020
- Fundamental
- Price
- SRTS $4.67
- PLRX $1.20
- Analyst Decision
- SRTS Strong Buy
- PLRX Hold
- Analyst Count
- SRTS 3
- PLRX 10
- Target Price
- SRTS $11.67
- PLRX $9.79
- AVG Volume (30 Days)
- SRTS 56.4K
- PLRX 1.5M
- Earning Date
- SRTS 08-07-2025
- PLRX 08-06-2025
- Dividend Yield
- SRTS N/A
- PLRX N/A
- EPS Growth
- SRTS N/A
- PLRX N/A
- EPS
- SRTS 0.11
- PLRX N/A
- Revenue
- SRTS $39,488,000.00
- PLRX N/A
- Revenue This Year
- SRTS $4.33
- PLRX N/A
- Revenue Next Year
- SRTS $31.55
- PLRX N/A
- P/E Ratio
- SRTS $42.60
- PLRX N/A
- Revenue Growth
- SRTS 24.75
- PLRX N/A
- 52 Week Low
- SRTS $4.01
- PLRX $1.10
- 52 Week High
- SRTS $9.33
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- SRTS 47.56
- PLRX 34.60
- Support Level
- SRTS $4.50
- PLRX $1.23
- Resistance Level
- SRTS $4.99
- PLRX $1.43
- Average True Range (ATR)
- SRTS 0.20
- PLRX 0.11
- MACD
- SRTS -0.02
- PLRX -0.02
- Stochastic Oscillator
- SRTS 33.54
- PLRX 8.33
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.